HomeInsightsStock Comparison

Cipla Ltd vs Dr Reddys Laboratories Ltd Stock Comparison

Cipla Ltd vs Dr Reddys Laboratories Ltd Stock Comparison

Last Updated on: May 28, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1477 as of 28 May 09:15.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 29.3 on March 2024 . This represents a CAGR of 5.90% over 5 yearsThe P/E Ratio of Dr Reddys Laboratories Ltd changed from 25.6 on March 2020 to 18.4 on March 2024 . This represents a CAGR of -6.39% over 5 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 120673 crore on March 2024 . This represents a CAGR of 28.75% over 5 yearsThe Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 51797 crore on March 2020 to ₹ 102679 crore on March 2024 . This represents a CAGR of 14.67% over 5 years.
  • The revenue of Cipla Ltd for the Mar '25 is ₹ 7019 crore as compare to the Dec '24 revenue of ₹ 7294 crore. This represent the decline of -3.78% The revenue of Dr Reddys Laboratories Ltd for the Mar '25 is ₹ 9056 crore as compare to the Dec '24 revenue of ₹ 8535 crore. This represent the growth of 6.1%.
  • The ebitda of Cipla Ltd for the Mar '25 is ₹ 1827 crore as compare to the Dec '24 ebitda of ₹ 2210 crore. This represent the decline of -17.35% The ebitda of Dr Reddys Laboratories Ltd for the Mar '25 is ₹ 2525 crore as compare to the Dec '24 ebitda of ₹ 2427 crore. This represent the growth of 4.04%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1225 crore over 8 quarters. This represents a CAGR of 10.87% The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1405 crore to ₹ 1586 crore over 8 quarters. This represents a CAGR of 6.27% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.74 % on March 2024 . This represents a CAGR of 12.57% over 5 yearsThe Dividend Payout of Dr Reddys Laboratories Ltd changed from 14.14 % on March 2020 to 15.37 % on March 2024 . This represents a CAGR of 1.68% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Limited is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Dr Reddys Laboratories Ltd

  • Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
  • Dr. Reddy's operates in markets across the globe.
  • Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

Cipla Ltd News Hub

News

Cipla to convene AGM

Cipla announced that the 89th Annual General Meeting(AGM) of the company will be held on 1...

Read more

14 May 2025 15:08

News

Board of Cipla recommends final dividend

Cipla announced that the Board of Directors of the Company at its meeting held on 13 May 2...

Read more

13 May 2025 14:34

News

Board of Cipla recommends special dividend

Cipla announced that the Board of Directors of the Company at its meeting held on 13 May 2...

Read more

13 May 2025 14:34

News

Cipla registers PAT of Rs 1,222 crore in Q4; EBITDA margin rises to 22.8%

On the segmental front, the company's India business revenue was Rs 2,622 crore (up 8% YoY...

Read more

13 May 2025 15:17

News

Cipla's Goa API facility receives VAI status from USFDA

According to an exchange filing dated 20 January 2025, the USFDA conducted an inspection o...

Read more

21 Apr 2025 11:32

News

Cipla allots 23,282 equity shares under ESOS

Cipla has allotted 23,282 fully paid-up equity shares of Rs 2 each, pursuant to exercise o...

Read more

17 Apr 2025 16:12

Dr Reddys Laboratories Ltd News Hub

News

Dr Reddys Labs' manufacturing facility gets two form 483 observations from US FDA

In a regulatory filing made on Saturday (24 May 2025), the company informed that the US FD...

Read more

26 May 2025 09:33

News

DRL's USA facility gets 2 observations from USFDA

The USFDA completed aforementioned inspection and issued form-483 with two observations. H...

Read more

19 May 2025 08:32

News

USFDA completes GMP inspection of Dr Reddy's Middleburgh facility in New York

Dr Reddys Laboratories announced that the United States Food & Drug Administration (USFDA)...

Read more

17 May 2025 11:32

News

Dr Reddys Lab jumps after Q4 PAT rises 22% YoY

Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 cror...

Read more

12 May 2025 14:50

News

Dr Reddys Laboratories AGM scheduled

Dr Reddys Laboratories announced that the 41th Annual General Meeting(AGM) of the company ...

Read more

10 May 2025 10:17

News

Dr Reddys Lab Q4 PAT rises 22% YoY

Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 cror...

Read more

10 May 2025 10:52

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Dr Reddys Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Dr Reddys Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Dr Reddys Laboratories Ltd

Which company has a larger market capitalization, Cipla Ltd or Dr Reddys Laboratories Ltd?

Market cap of Cipla Ltd is 119,559 Cr while Market cap of Dr Reddys Laboratories Ltd is 103,747 Cr

What are the key factors driving the stock performance of Cipla Ltd and Dr Reddys Laboratories Ltd?

The stock performance of Cipla Ltd and Dr Reddys Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Dr Reddys Laboratories Ltd?

As of May 28, 2025, the Cipla Ltd stock price is INR ₹1480.35. On the other hand, Dr Reddys Laboratories Ltd stock price is INR ₹1243.3.

How do dividend payouts of Cipla Ltd and Dr Reddys Laboratories Ltd compare?

To compare the dividend payouts of Cipla Ltd and Dr Reddys Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions